Indraprastha Medical Corporation Limited (NSE:INDRAMEDCO)
India
· Delayed Price · Currency is INR 393.00
-5.10 (-1.28%)
Jun 23, 2025, 1:27 PM IST
NSE:INDRAMEDCO Revenue
In the fiscal year ending March 31, 2025, Indraprastha Medical Corporation had annual revenue of 13.56B INR with 8.97% growth. Indraprastha Medical Corporation had revenue of 3.34B in the quarter ending March 31, 2025, with 6.04% growth.
Revenue
13.56B
Revenue Growth
+8.97%
P/S Ratio
2.69
Revenue / Employee
4.56M
Employees
2,977
Market Cap
36.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 13.56B | 1.12B | 8.97% |
| Mar 31, 2024 | 12.45B | 1.46B | 13.29% |
| Mar 31, 2023 | 10.99B | 2.11B | 23.70% |
| Mar 31, 2022 | 8.88B | 2.75B | 44.80% |
| Mar 31, 2021 | 6.13B | -2.17B | -26.17% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |